SCHEMBL10165828

SCHEMBL10165828

N[C@@H](CC(=O)O)C(=O)N[C@H](CCC(=O)O)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 5/20 0.58
NAALAD2 Q9Y3Q0 3/20 0.58
RIMKLA Q8IXN7 1/20 0.58
GRM8 O00222 1/20 0.48
GRM6 O15303 1/20 0.48
GRIN2D O15399 1/20 0.48
GRIN3B O60391 1/20 0.48
GSR P00390 1/20 0.48
CYP1A2 P05177 1/20 0.48
GRIK1 P39086 1/20 0.48
GRM5 P41594 1/20 0.48
GRIA1 P42261 1/20 0.48
GRIA2 P42262 1/20 0.48
GRIA3 P42263 1/20 0.48
SLC1A3 P43003 1/20 0.48
SLC1A2 P43004 1/20 0.48
SLC1A1 P43005 1/20 0.48
GRIA4 P48058 1/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2A Q12879 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1276945 1.00 FOLH1 (0.58) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL18557284 1.00 FOLH1 (0.58) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL30760990 1.00 FOLH1 (0.58) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL27599412 1.00 FOLH1 (0.58) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL1276949 1.00 FOLH1 (0.58) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL28489878 0.97 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL29517538 0.97 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL29511419 0.97 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL30798162 0.97 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL29682236 0.97 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116670268-A Fusion proteins comprising E2 ubiquitin or ubiquitin-like conjugation domains and targeting domains for specific protein degradation 免疫医疗有限公司 2023-08-29 CN disclosed
CN-114702581-A Universal carbohydrate compositions and methods for enhancing antibody efficacy 台湾地区“中央研究院” 2022-07-05 CN disclosed
CN-114437173-A Novel peptides and uses thereof 森纳生物科学公司 2022-05-06 CN disclosed
US-20210177857-A1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME PFIZER INC. (US) 2021-06-17 US disclosed
US-10952972-B2 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same PFIZER INC. (US) 2021-03-23 US disclosed
EP-3511019-B1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME PFIZER (US) 2020-10-14 EP disclosed
EP-2774608-B1 Drug loaded polymeric nanoparticles and methods of making and using same PFIZER (US) 2019-11-20 EP disclosed
US-20190269617-A1 Methods of Controlling Morphology of Polymeric Nanoparticles PFIZER INC. (US) 2019-09-05 US disclosed
EP-3511019-A1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME Pfizer Inc (US) 2019-07-17 EP disclosed
EP-3116547-B1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME PFIZER (US) 2019-06-05 EP disclosed
US-8420123-B2 Drug loaded polymeric nanoparticles and methods of making and using same BIND BIOSCIENCES, INC. (US) 2013-04-16 US disclosed
US-20120288541-A1 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same PFIZER INC. 2012-11-15 US disclosed
US-8293276-B2 Drug loaded polymeric nanoparticles and methods of making and using same BIND BIOSCIENCES, INC. (US) 2012-10-23 US disclosed
US-8236330-B2 Cancer cell targeting using nanoparticles BIND BIOSCIENCES, INC. (US) 2012-08-07 US disclosed
US-8206747-B2 Drug loaded polymeric nanoparticles and methods of making and using same BIND BIOSCIENCES, INC. (US) 2012-06-26 US disclosed
EP-2436376-A1 Cancer cell targeting using nanoparticles Bind Biosciences, Inc. (US) 2012-04-04 EP disclosed
US-20110274759-A1 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same PFIZER INC. 2011-11-10 US disclosed
US-20110224288-A1 Cancer Cell Targeting Using Nanoparticles PFIZER INC. 2011-09-15 US disclosed
US-20100068285-A1 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same PFIZER INC. 2010-03-18 US disclosed
WO-2008121949-A1 CANCER CELL TARGETING USING NANOPARTICLES BIND BIOSCIENCES, INC. (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110274759-A1 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same LDHA, LDHB, LPXN FOLH1 177/4885NAALAD2 2442/4885RIMKLA 1489/4885
US-20110224288-A1 Cancer Cell Targeting Using Nanoparticles CD47, EPCAM, CD44 FOLH1 279/4885NAALAD2 1525/4885RIMKLA 3697/4885
US-20100068285-A1 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same CD47, LPXN, CD44 FOLH1 173/4885NAALAD2 2614/4885RIMKLA 1707/4885
US-20190269617-A1 Methods of Controlling Morphology of Polymeric Nanoparticles CLTB, NCL, ACTB FOLH1 828/4885NAALAD2 3320/4885RIMKLA 1643/4885
US-10952972-B2 Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same CTSA, GAA, EEA1 FOLH1 135/4885NAALAD2 1736/4885RIMKLA 3209/4885
US-20120288541-A1 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same CD47, LPXN, CD44 FOLH1 173/4885NAALAD2 2614/4885RIMKLA 1707/4885
US-20210177857-A1 THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME TP53, HNRNPH3, VHL FOLH1 336/4885NAALAD2 1694/4885RIMKLA 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.